- NEWS
- RESEARCH PIPELINE
- CLINICAL TRIALS
- REPORTS LIBRARY
- HD GLOSSARY
- MILESTONES
- LINKS TO OTHER RESEARCH
- GRANT APPLICATIONS
- PAST & FUTURE
- STEM CELLS
- COGNITIVE ASSESSMENT BATTERY STUDY
- HSG CLINICAL RESEARCH SYMPOSIUM 2011
- JOURNAL OF HUNTINGTON'S DISEASE
- NINDS HD COMMON DATA ELEMENTS
- INDIANA UNIVERSITY STUDY ANNOUNCEMENT
Research Reports Library
Here you will find copies of HDSA Research Reports that have been featured on the HDSA website and in our print publications. To read or download a report just click on the title.
2011 reports
TRACK-HD Identifies Candidate Biomarkers Based on a Two Year Longitudinal Study
The Muscle Relaxant Dantrolene is Neuroprotective in an HD Mouse Model
The Form of the HD Protein Associated with Neurodegeneration is Identified
Melatonin Delays Onset in HD Mouse Model
Biomarker for HD Identified
Oxidation. Oligomerization, Copper, and Protein Clearance: The Prana Trial
KMO Inhibitor Increases Suvival Time by 40 Percent in the HD Mice
Quinazoline Derivative may treat Huntington's disease
Phosphodiesterase-10A inhibitors moving through the pipeline
Progression of Huntington's Disease
Huntingtin Aggregates Visualized at Oak Ridge Laboratory
Dr. Ray Truant and Colleagues Publish Promising Findings
A New Mouse Model of HDL2, a very rare disorder similar to HD
Interview with Steven Hersch on the CREST-E Trial
Siena Biotech Starts Phase II Trial of its SIRT1 Inhibitor in Europe
Why Mechanism Matters: The Case of Dimebon
DRP1 Identified as Promising Therapeutic Target
A Drug in Trials for MS is Helpful to HD Mice
A New Drug May be Neuroprotective in HD
Novel Compounds Developed to Protect Brain from Neurodegeneration
New Caspase Six Inhibitors Identified and Optimized
Exercise found harmful in a mouse model of HD
2010 reports
Everolimus not neuroprotective in the R6/2 mice
HART (ACR16) trial results announced - encouraging but not conclusive
Metalloproteinases - new therapeutic targets
2010 HDSA Convention Notes: Research Forum
2010 HDSA Convention Notes: Potential New Therapies
Press Release: Prana Biotechnology's PBT2 is in development for HD and AD
Sirtuin Inhibition Achieves Neuroprotection by Decreasing Sterol Biosynthesis
New Insights About Protein Aggregation
Mesenchymal Stem Cells are Helpful in the YAC128 Mouse Models
News from Raptor Pharmaceuticals
CoQ10 and Minocycline Not Helpful in a Mouse Model
Cargo Recognition is Impaired in Autophagy
RNA Interference in a Clinical Trial for Melanoma Patients
Neurosearch Presents Additional Huntexil (ACR16) Data
Disappointing results in a Phase III Trial of Dimebon in Alzheimer's
Phase II Dimebon results are reported in an academic journal
More on Extrasynaptic Activity and Memantine in the HD Mice
A Sirtuin Inhibitor Enters Phase I Clinical Trials in Europe
A Molecular Switch: Studies of Phosphorylation
2009 reports
The 2009 Huntington's Disease Clinical Research Symposium
Synaptic Activity, Extrasynaptic Activity, and Memantine
The Search for Genetic Modifiers
Track-HD reports baseline findings
Strattera found ineffective in treating cognition in HD patients
Interview with Jan Nolta on stem cells
Mesenchymal stem cells in an animal model
FDA grants Dimebon orphan drug status
Cogane, a new BDNF inducer, enters the drug pipeline for HD
A breakthrough in generating stem cells from adult cells
Axonal transport is impaired in HD
Medivation to begin a Phase III trial of Dimebon
A new caspase six inhibitor is developed
Indiana researchers get NIH funding for HD research
Minocycline Phase II trial results disappointing
Acetylation of the HD protein - a new therapeutic target
An ampakine upregulates BNDF and improves memory
Stem cell research proceeds with hope and caution
Obama signs order lifting the ban on embryonic stem cell research
The ACR16 trial is enrolling participants
PGC-1 alpha gene modifies age of onset in HD
2008 reports
Weight loss in Huntington's Disease
Ethyl EPA (Miraxion) still in the pipeline
Huntington Study Group symposium 2008
ACR16 and cysteamine make progress in the pipeline
Nrf2 responsive genes are activated in HD
Ethyl-EPA reduces the rate of brain atrophy
An HDAC inhibitor ameliorates pathology in the R6/2 mice
Inhibitors of cytochrome c have therapeutic potential
CEP-1347 is added to the research pipeline
The Hereditary Disease Foundation Conference 2008
A New Stem Cell Line for HD: Another Model of the Disease
Immune System Over-Activated in HD
The FDA Approves a Phase IIb Clinical Trial of ACR16
Dimebon found safe and well tolerated in a Phase II trial
Sertaline helps two mouse models of HD
Raptor Pharmaceuticals Plan Phase II trial of Cysteamine
ALS clinical trial finds that minocycline accelerates disease progression
The Inaugural HSG Clinical Research Symposium
DIMOND (Dimebon Phase 2 Clinical Research Study) is Recruiting
first large transgenic animal model for Huntington's disease
Huntington Study Group Meetings Starting the Old and Planning for the New
Enrollment for DIMOND was completed in March 2008. Dimebon clinical trial is recruiting.
2008 CHDI HD Therapeutics Conference - A Report from an HD Family Perspective
Drugs which induce autophagy are added to the research pipeline
Early Neurotransmitter Problems in HD
Physical activity delays onset of motor symptoms in the R6/1 mouse model of HD
ALS clinical trial finds that minocycline accelerates disease progression
Yerkes researchers develop first transgenic nonhuman primate model of Huntington's disease
2007 Essays
The Huntington’s Disease Community’s Strategic Plan for the Cure
The Huntington’s Disease Community’s Strategic Plan for the Cure
The Huntington’s Disease Community’s Strategic Plan for the Cure